Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment

Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment

Background: Ipilimumab (IPI) and BRAF inhibitors (BRAFi) improve survival in melanoma, but not all patients will benefit and toxicity can be significant. Pretreatment neutrophil to lymphocyte ratio (NLR) has been associated with outcome in IPI-treated patients, but has not been studied during treatm...

Full description

Bibliographic Details
Main Authors: Michael R. Cassidy, Rachel E. Wolchok, Junting Zheng, Katherine S. Panageas, Jedd D. Wolchok, Daniel Coit, Michael A. Postow, Charlotte Ariyan
Format: Article
Language:English
Published: Elsevier 2017-04-01
Series:EBioMedicine
Subjects:
Neutrophil to lymphocyte ratio
NLR
Melanoma
Immunotherapy
BRAF inhibitors
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396417301251

Internet

http://www.sciencedirect.com/science/article/pii/S2352396417301251

Similar Items